Organized by the Foundation for the National Institutes of Health.

Microsoft Research is the partnering sponsor of the Summit. Other sponsors include the Abbott Fund, Battelle, Becton Dickinson, Johnson & Johnson, Qualcomm and Pfizer. This was the first time this varied group assembled for this type of cross-self-discipline collaboration. This smaller, private event was structured with support from the World Bank, mHealth Alliance, and the Foundation for NIH. Together we share a goal of opening new opportunities for cross-self-discipline collaboration and partnerships that deliver on the immense promise that mHealth holds: improving healthcare delivery, to underserved communities particularly, in the U.S.This is a treatment gap that adoptive T-cell therapy could fill potentially.

Advances in chemotherapy significantly reduce threat of disease recurrence in breasts cancer patients Latest advances in chemotherapy have significantly reduced the risk of disease recurrence and death in breast cancer patients whose tumors aren’t hormone sensitive, regarding to a scholarly research by researchers at Dana-Farber Cancer Institute and 10 additional institutions. The findings will be reported in Journal of the American Medical Association. The researchers found that breast cancer sufferers whose disease experienced spread to the lymph nodes and was estrogen-receptor-detrimental and who were received adjuvant treatments with contemporary chemotherapy had a much greater improvement in their five-year disease-free survival price than those patients with hormone sensitive tumors who were treated with the same chemotherapy and tamoxifen .